AU2023226618A1 - Formulations comprising acid-neutralizing polymer for oral administration of active agents - Google Patents

Formulations comprising acid-neutralizing polymer for oral administration of active agents Download PDF

Info

Publication number
AU2023226618A1
AU2023226618A1 AU2023226618A AU2023226618A AU2023226618A1 AU 2023226618 A1 AU2023226618 A1 AU 2023226618A1 AU 2023226618 A AU2023226618 A AU 2023226618A AU 2023226618 A AU2023226618 A AU 2023226618A AU 2023226618 A1 AU2023226618 A1 AU 2023226618A1
Authority
AU
Australia
Prior art keywords
composition
therapeutically active
acid
active agent
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023226618A
Other languages
English (en)
Inventor
Gregory Burshtein
Hillel GALITZER
Constantin ITIN
Phillip M. SCHWARTZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Entera Bio Ltd
Original Assignee
Entera Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entera Bio Ltd filed Critical Entera Bio Ltd
Publication of AU2023226618A1 publication Critical patent/AU2023226618A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2023226618A 2022-02-24 2023-02-23 Formulations comprising acid-neutralizing polymer for oral administration of active agents Pending AU2023226618A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263313363P 2022-02-24 2022-02-24
US63/313,363 2022-02-24
PCT/IL2023/050192 WO2023161934A1 (en) 2022-02-24 2023-02-23 Formulations comprising acid-neutralizing polymer for oral administration of active agents

Publications (1)

Publication Number Publication Date
AU2023226618A1 true AU2023226618A1 (en) 2024-10-03

Family

ID=87765060

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023226618A Pending AU2023226618A1 (en) 2022-02-24 2023-02-23 Formulations comprising acid-neutralizing polymer for oral administration of active agents

Country Status (10)

Country Link
US (1) US20250186558A1 (cg-RX-API-DMAC7.html)
EP (1) EP4482507A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025506821A (cg-RX-API-DMAC7.html)
KR (1) KR20240152915A (cg-RX-API-DMAC7.html)
CN (1) CN119053335A (cg-RX-API-DMAC7.html)
AU (1) AU2023226618A1 (cg-RX-API-DMAC7.html)
CA (1) CA3251862A1 (cg-RX-API-DMAC7.html)
IL (1) IL315198A (cg-RX-API-DMAC7.html)
MX (1) MX2024010387A (cg-RX-API-DMAC7.html)
WO (1) WO2023161934A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025046589A1 (en) * 2023-08-30 2025-03-06 Entera Bio Ltd. Formulations comprising a combination of acid-neutralizing polymeric and non-polymeric substances for oral administration of active agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5175553B2 (ja) * 2005-02-01 2013-04-03 エミスフェアー・テクノロジーズ・インク 胃内滞留および制御放出型送達系
WO2008070543A1 (en) * 2006-12-01 2008-06-12 Emisphere Technologies Inc. Improved acyclovir formulations
US20090124639A1 (en) * 2007-11-06 2009-05-14 Emisphere Technologies Inc. valacyclovir formulations
WO2016128972A1 (en) * 2015-02-09 2016-08-18 Entera Bio Ltd. Formulations for oral administration of active agents with controlled absorption profile
MX2019001850A (es) * 2016-08-17 2019-05-15 Entera Bio Ltd Formulaciones para administracion oral de principios activos.
WO2018121702A1 (zh) * 2016-12-30 2018-07-05 江苏恒瑞医药股份有限公司 一种glp-1类似物的药物组合物及其制备方法
CN112587496A (zh) * 2020-12-16 2021-04-02 江苏海洋大学 一种艾塞那肽肠溶胶囊及其制备方法

Also Published As

Publication number Publication date
JP2025506821A (ja) 2025-03-13
CN119053335A (zh) 2024-11-29
WO2023161934A1 (en) 2023-08-31
MX2024010387A (es) 2024-09-04
EP4482507A1 (en) 2025-01-01
IL315198A (en) 2024-10-01
US20250186558A1 (en) 2025-06-12
EP4482507A4 (en) 2026-02-18
CA3251862A1 (en) 2023-08-31
KR20240152915A (ko) 2024-10-22

Similar Documents

Publication Publication Date Title
KR101200227B1 (ko) 글루카곤 유사 펩티드-2(glp-2) 유사체
EP3256152A1 (en) Treatment of bone fractures and defects
US20260124281A1 (en) Formulations comprising acid-neutralizing polymer for oral administration of parathyroid hormone
WO2023161939A1 (en) Formulations comprising acid-neutralizing polymer for oral administration of glucagon-like peptide-1 and analogs thereof
EP4482507A1 (en) Formulations comprising acid-neutralizing polymer for oral administration of active agents
WO2023161938A1 (en) Formulations comprising acid-neutralizing polymer for oral administration of kappa opioid receptor agonist peptide
WO2025046589A1 (en) Formulations comprising a combination of acid-neutralizing polymeric and non-polymeric substances for oral administration of active agents
WO2025046590A1 (en) Formulations for oral administration of active agents
US20250186555A1 (en) Formulations comprising acid-neutralizing polymer for oral administration of glucagon-like peptide-2
WO2023161935A1 (en) Formulations comprising acid-neutralizing polymer for oral administration of growth hormone
WO2023161936A1 (en) Formulations comprising acid-neutralizing polymer for oral administration of growth hormone-releasing hormone
HK40101653A (en) Formulations for oral administration of active agents
HK40101429A (en) Formulations for oral administration of active agents